SMARCA4 deficiency in glioblastoma: Mitochondrial transfer from MSCs and the clinical dilemma in targeting the tumor microenvironment

Key Points

• Mitochondrial transfer from mesenchymal stem cells appears to enhance glioblastoma progression.
• Patients with SMARCA4-deficient glioblastomas show altered tumor biology and potentially resist treatment.
• This approach indicates a complex interaction between tumor cells and the tumor microenvironment affecting disease outcome.
• Highlighting the need for nuanced therapeutic strategies in targeting SMARCA4-related glioblastomas.